NEW YORK (GenomeWeb) – Bayer CropScience today said that it is investing almost $1 billion in capital expenditures in the US between 2013 and 2016 to build up its R&D capabilities and expand its supply of crop protection brands.

The funding is part of a global investment program that Bayer CropScience began last year with total capital expenditures of €2.4 billion ($3.3 billion) between 2013 and 2016.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.